Invention Grant
- Patent Title: Agents for treatment of claudin expressing cancer diseases
-
Application No.: US14442445Application Date: 2013-11-12
-
Publication No.: US10093736B2Publication Date: 2018-10-09
- Inventor: Ugur Sahin , Ozlem Tureci , Christiane Stadler , Julia Holland , Hayat Bahr-Mahmud , Tim Beissert , Laura Plum , Fabrice Le Gall , Arne Jendretzki , Markus Fiedler
- Applicant: Biontech AG , Ganymed Pharmaceuticals AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
- Applicant Address: DE Mainz DE Mainz DE Mainz DE Mainz
- Assignee: BIONTECH AG,TRON GGMBH,UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ,GANYMED PHARMACEUTICALS AG
- Current Assignee: BIONTECH AG,TRON GGMBH,UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ,GANYMED PHARMACEUTICALS AG
- Current Assignee Address: DE Mainz DE Mainz DE Mainz DE Mainz
- Agency: Ballard Spahr LLP
- Priority: WOPCT/EP2012/004712 20121113; WOPCT/EP2013/002270 20130730
- International Application: PCT/EP2013/003399 WO 20131112
- International Announcement: WO2014/075788 WO 20140522
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K39/00
Abstract:
The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Public/Granted literature
- US20160272711A1 Agents for Treatment of Claudin Expressing Cancer Diseases Public/Granted day:2016-09-22
Information query
